Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02032914
Other study ID # 1
Secondary ID
Status Completed
Phase Phase 4
First received January 8, 2014
Last updated February 26, 2016
Start date January 2014
Est. completion date February 2016

Study information

Verified date February 2016
Source Inje University
Contact n/a
Is FDA regulated No
Health authority Korea: Ministry for Health and Welfare
Study type Observational [Patient Registry]

Clinical Trial Summary

Although a proportion of pyogenic liver abscess may originated from colonic mucosal lesions, the prevalence of colonic neoplasm in the patients with pyogenic liver abscess are still not evaluated yet. Thus, our group will find the prevalence of colonic neoplasm in the group of cryptogenic pyogenic liver abscess by colonoscopic examination.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date February 2016
Est. primary completion date February 2016
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Pyogenic liver abscess radiologically and bacteriologically diagnosed

Exclusion Criteria:

- Amebic liver abscess

- Other causes of pyogenic liver abscess such as cholangitis, liver cancer, complication of transarterial chemoembolization or radiofrequency ablation to hepatocellular carcinoma

- Refusal to colonoscopic examination

- Inadequate general patient status to perform the colonoscopic examination

- Patient who has had the screening colonoscopic examination within 1 year and showed normal finding or had 1 or 2 colon polyp in adequate exam

Study Design

Observational Model: Case-Only, Time Perspective: Cross-Sectional


Related Conditions & MeSH terms


Locations

Country Name City State
Korea, Republic of Inje University Haeundae Paik Hospital Busan
Korea, Republic of Pusan National Unversity Yangsan Hospital Yangsan-si Gyeongsangnam-do

Sponsors (2)

Lead Sponsor Collaborator
Inje University Pusan National University Yangsan Hospital

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary The prevalence of colonic neoplasm within 6 weeks after diagnosis of pyogenic liver abscess No
Secondary Prevalence of colon polyp Within 6 weeks at diagnosis of pyogenic liver abscess No
Secondary Prevalence of colonic diverticulitis Within 6 weeks at diagnosis of pyogenic liver abscess No
Secondary Prevalence of inflammatory bowel disease Within 6 weeks at diagnosis of pyogenic liver abscess No
Secondary Prevalence of intestinal tuberculosis Within 6 weeks at diagnosis of pyogenic liver abscess No